Management of Right Ventricular Thrombus

Risk Stratification and Initial Assessment

Mobile right heart thrombi are detected in less than 4% of patients with pulmonary embolism, but may reach 18% among patients in intensive care settings, according to the European Respiratory Journal 1
Right heart thrombi confirm the diagnosis of pulmonary embolism and are associated with high early mortality, especially in patients with right ventricular dysfunction, as reported by the European Respiratory Journal 1, 2
Patients with right heart thrombi typically present with lower systemic blood pressure, higher prevalence of hypotension, higher heart rate, and more frequent right ventricular hypokinesis compared to other pulmonary embolism patients, according to the European Heart Journal 3
Immediate echocardiographic assessment is crucial for diagnosis and risk stratification, with transthoracic or transesophageal echocardiography being the primary diagnostic tools, as recommended by the European Respiratory Journal 1, 2

Immediate therapeutic anticoagulation should be initiated in all patients with right ventricular thrombus, as recommended by the European Heart Journal 4, 1
Unfractionated heparin is preferred initially due to its short half-life and reversibility, especially if more invasive interventions might be needed, according to the European Heart Journal 4
Transition to oral anticoagulation should be considered for long-term management, with a target INR of 2-3, as recommended by Circulation 5

Systemic thrombolysis is recommended as first-line treatment in patients with high-risk pulmonary embolism presenting with cardiogenic shock and/or persistent arterial hypotension, as recommended by the European Heart Journal 4, 6
Thrombolysis has shown favorable outcomes in patients with mobile right heart thrombi, with reports of clot disappearance from the right heart within 2, 12, and 24 hours after administration, according to the European Heart Journal 3
Observational data suggest thrombolysis is associated with better outcomes than anticoagulation alone in patients with right-sided heart thrombus in transit, as reported by Circulation 7, 8

Catheter-directed interventions should be considered for patients with contraindications to systemic thrombolysis or those who have failed thrombolytic therapy, as recommended by the European Heart Journal 4, 9
Options include catheter-directed thrombolysis, thrombus fragmentation, rheolytic thrombectomy, suction thrombectomy, and rotational thrombectomy, according to the European Heart Journal 9

Surgical pulmonary embolectomy should be considered in patients with contraindications to thrombolysis, failed thrombolysis, or right heart thrombi straddling the interatrial septum through a patent foramen ovale, as recommended by the European Heart Journal 4, 9
Surgical embolectomy has been associated with better outcomes than anticoagulation alone in patients with right-sided heart thrombus in transit, as reported by Circulation 7, 8

Hemodynamically unstable patients with high-risk pulmonary embolism should receive immediate systemic thrombolysis if no absolute contraindications exist, as recommended by the European Heart Journal 4, 6
Hemodynamically stable patients with right ventricular dysfunction should start with therapeutic anticoagulation, and consider thrombolysis or surgical embolectomy for mobile right heart thrombi, according to the European Heart Journal 4, 6

Continuous monitoring of vital signs, oxygen saturation, and hemodynamic parameters is essential, as recommended by the European Heart Journal 10
Serial echocardiographic assessments should be performed to monitor right ventricular function and thrombus resolution, according to the European Heart Journal 10
Long-term anticoagulation is necessary to prevent recurrence, typically for 3-6 months minimum, as recommended by Circulation 5